20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Repligen Corporation (RGEN) operates in the MEDICAL INSTRUMENTS & SUPPLIES industry and is headquartered in Waltham, United States with about 2,000 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, RGEN reported $738M in revenue and $49M in net income.
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Interactive charts & full statements → Open the RGEN valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $785M | $738M | $634M | $639M | $802M | $671M | $366M | $270M | $194M | $141M | $105M | $84M | $64M | $68M | $62M | $23.4B | $27M | $21M | $29M | $19M | $14M |
| Gross Profit | $401M | $348M | $275M | $284M | $456M | $391M | $194M | $138M | $108M | $74M | $57M | $48M | $36M | $43M | $35M | $17.0B | $20M | $15M | $23M | $13M | $10M |
| Gross Margin % | 51.0% | 47.1% | 43.3% | 44.5% | 56.9% | 58.4% | 53.1% | 51.1% | 55.7% | 52.5% | 54.9% | 57.8% | 55.9% | 63.1% | 56.4% | 72.4% | 73.9% | 73.7% | 76.9% | 68.1% | 74.3% |
| Operating Income (EBIT) | $65M | $60M | ($35M) | $55M | $225M | $167M | $81M | $40M | $26M | $14M | $16M | $14M | $11M | $23M | $11M | ($1.1B) | $0M | ($6M) | $4M | $36M | ($2M) |
| Operating Margin % | 8.3% | 8.1% | -5.5% | 8.5% | 28.0% | 24.9% | 22.2% | 14.8% | 13.4% | 9.9% | 15.3% | 16.5% | 16.8% | 33.6% | 17.8% | -4.7% | -1.4% | -27.5% | 13.2% | 186.0% | -13.0% |
| Net Income | $42M | $49M | ($26M) | $42M | $186M | $128M | $60M | $21M | $17M | $28M | $12M | $9M | $8M | $16M | $14M | ($1.6B) | $0M | ($4M) | $6M | $37M | ($1M) |
| Net Margin % | 5.3% | 6.6% | -4.0% | 6.5% | 23.2% | 19.1% | 16.4% | 7.9% | 8.6% | 20.1% | 11.2% | 11.2% | 12.9% | 23.6% | 22.7% | -6.9% | -0.2% | -19.4% | 19.6% | 192.3% | -6.3% |
| EBITDA | $122M | $164M | $80M | $124M | $277M | $203M | $98M | $56M | $42M | $24M | $25M | $22M | $15M | $26M | $15M | ($322M) | $0M | $2M | ($4M) | $7M | $37M |
| Earnings Per Share (EPS) | $0.73 | $0.86 | $-0.46 | $0.74 | $3.24 | $2.24 | $1.11 | $0.44 | $0.37 | $0.72 | $0.34 | $0.28 | $0.25 | $0.50 | $0.45 | $-52.40 | $-0.00 | $-0.13 | $0.18 | $1.18 | $-0.03 |
| Shares Outstanding (M) | 57M | 57M | 56M | 56M | 57M | 57M | 54M | 49M | 45M | 39M | 34M | 34M | 33M | 32M | 31M | 31M | 31M | 31M | 31M | 31M | 30M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $204M | $194M | $198M | $189M | $182M | $169M | $168M | $155M |
| Gross Profit | $108M | $98M | $93M | $101M | $91M | $91M | $39M | $77M |
| Gross Margin % | 53.1% | 50.7% | 47.2% | 53.2% | 50.0% | 53.6% | 23.2% | 50.0% |
| Operating Income (EBIT) | $12M | $18M | $19M | $17M | $14M | $7M | ($37M) | ($8M) |
| Operating Margin % | 5.8% | 9.3% | 9.4% | 8.9% | 7.6% | 3.9% | -21.8% | -5.1% |
| Net Income | $5M | $8M | $13M | $15M | $15M | $6M | ($34M) | ($1M) |
| Net Margin % | 2.5% | 4.3% | 6.7% | 7.9% | 8.2% | 3.5% | -20.2% | -0.4% |
| EBITDA | ($2M) | $32M | $45M | $47M | $48M | $36M | $2M | $21M |
| Earnings Per Share (EPS) | $0.09 | $0.15 | $0.24 | $0.26 | $0.26 | $0.10 | $-0.60 | $-0.01 |
| Shares Outstanding (M) | 57M | 57M | 57M | 57M | 57M | 57M | 56M | 57M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $135M | $117M | $175M | $114M | $172M | $119M | $63M | $67M | $33M | $17M | $8M | $15M | $18M | $26M | $13M | $2M | $3M | ($2M) | $6M | $38M | $0M |
| Capital Expenditures (CapEx) | $24M | $24M | $33M | $39M | $133M | $67M | $26M | $23M | $14M | $5M | $4M | $3M | $6M | $5M | $1M | $575M | $1M | $1M | $1M | $1M | $1M |
| Free Cash Flow (FCF) | $111M | $94M | $142M | $75M | $39M | $52M | $36M | $44M | $19M | $12M | $3M | $12M | $13M | $21M | $12M | ($573M) | $3M | ($3M) | $5M | $37M | ($1M) |
| FCF Margin % | 14.1% | 12.7% | 22.5% | 11.7% | 4.8% | 7.7% | 9.9% | 16.3% | 9.7% | 8.5% | 3.1% | 14.9% | 20.1% | 31.2% | 19.6% | -2.4% | 9.9% | -14.5% | 16.9% | 193.6% | -6.5% |
| Dividends Paid | — | — | — | $566M | $17M | $3M | — | $0M | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $33M | $28M | $26M | $48M | $29M | $15M | $39M | $49M |
| Capital Expenditures (CapEx) | $5M | $5M | $9M | $5M | $8M | $4M | $7M | $7M |
| Free Cash Flow (FCF) | $28M | $23M | $17M | $43M | $21M | $11M | $32M | $42M |
| FCF Margin % | 13.6% | 12.0% | 8.6% | 22.6% | 11.5% | 6.2% | 19.2% | 27.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.0B | $3.0B | $2.8B | $2.8B | $2.5B | $2.4B | $1.9B | $1.4B | $139M | $120M | $289M | $146M | ($65M) | $119M | $97M | $76M | $72M | $71M | $74M | $69M | $29M |
| Cash & Cash Equivalents | $607M | $566M | $757M | $751M | $523M | $604M | $717M | $528M | $194M | $174M | $142M | $73M | $62M | $40M | $29M | $11M | $14M | $13M | $5M | $33M | $8M |
| Total Liabilities | $838M | $844M | $857M | $853M | $621M | $608M | $374M | $340M | $159M | $152M | $120M | $23M | $17M | $15M | $13M | $10M | $5M | $5M | $5M | $5M | $5M |
| Total Debt (Short + Long-Term) | $570M | $564M | $541M | $585M | $292M | $264M | $249M | $236M | $103M | $198M | $191M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $2M |
| Total Shareholders' Equity | $2.1B | $2.1B | $2.0B | $2.0B | $1.9B | $1.8B | $1.5B | $1.1B | $616M | ($32M) | $169M | $123M | $112M | $104M | $84M | $66M | $67M | $67M | $66M | $69M | $64M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RGEN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms